Prescribing antidepressants to pregnant women: What is a family physician to do?;Prescrire des antidépresseurs aux femmes enceintes: Que doivent faire les médecins de famille?

Canadian Family Physician

Volumn 53, Issue 9, 2007, Pages

  Einarson, Adrienne ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

BIRTH DEFECT; DEPRESSION; HEALTH CARE PERSONNEL; HEALTH HAZARD; HUMAN; LOW BIRTH WEIGHT; NOTE; PATIENT SAFETY; PREGNANCY; PRESCRIPTION; PULMONARY HYPERTENSION; ARTICLE; CANADA; DRUG SCREENING; FEMALE; GENERAL PRACTICE; METHODOLOGY; NEWBORN; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; CANADA; DEPRESSION; DRUG EVALUATION; FAMILY PRACTICE; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 35748974210     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (21)

1. Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician 2005;51:1087-93.
2. GlaxoSmithKline. New safety information regarding paroxetine: findings suggest increased risk over other antidepressants, of congenital malformations, following first trimester exposure to paroxetine. Mississauga, Ont: GlaxoSmithKline; 2005. Accessible à: http://www.gsk.ca/en/health_info/ PAXIL_PregnancyDHCPL_E-V4.pdf. Accédé le 15 juillet 2007.
3. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21(3):221-2.
4. Diav-Citrin O, Shechtman S, Weinbaum D, Arnon J, Di Gianantonio E, Clementi M, et al. Paroxetine and fluoxetine in pregnancy: controlled study [résumé]. Reprod Toxicol 2005;20:459.
5. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354(6):579-87.
6. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63(8):898-906.
7. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17(6):701-4.
8. Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? CMAJ 2005;172(11):1457-9.
9. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160(2):173-6.
10. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-7.
11. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194(4):961-6.
12. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106(6):1289-96.
13. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WE, Panchaud A, et al. Paroxetine use in pregnancy: is there an association with congenital cardiovascular defects? Proceedings of the Teratology Society meeting [résumé]. Pittsburgh, Penn; juin 2007, Volume 79 Numéro 5: p. 358.
14. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39(12):1890-900.
15. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM; National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356(26):2684-92.
16. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356(26):2675-83.
17. Wichman CL, Moore KM, Lang TR, Heise RH, Watson WJ, et al. Prevalence of serotonin specific reuptake inhibitor (SSRI) use in pregnant women. Résumé NR41 présenté le 21 mai dans les comptes rendus du congrès de l'American Psychiatric Association. San Deigo, Calif; mai 2007.
18. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295(5):499-507.
19. Bar-Oz B, Einarson TR, Einarson A, Boskovic R, O'Brien L, Malm H, et al. Paroxetine and congenital malformations; meta-analysis and consideration of potential confounders. Clin Therapeut 2007;29(5):918-26.
20. Flynn HA, Blow FC, Marcus SM. Rates and predictors of depression treatment among pregnant women in hospital-affiliated obstetrics practices. Gen Hosp Psychiatry 2006;28(4):289-95.
21. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs due to fears of teratogenic risk and the impact of counseling. J Psychiatry Neurosci 2001;26:44-8.